Verition Fund Management
RIGL icon

Verition Fund Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Verition Fund Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,489
Closed -$382K – 3874
2025
Q3 		$382K Buy
+13,489
New +$404K ﹤0.01% 3173
2025
Q1 		– Sell
-15,953
Closed -$268K – 3656
2024
Q4 		$268K Buy
+15,953
New +$306K ﹤0.01% 2826
2024
Q1 		– Sell
-1,147
Closed -$16.6K – 2948
2023
Q4 		$16.6K Buy
+1,147
New +$11.7K ﹤0.01% 2218
2023
Q3 		– Sell
-8,924
Closed -$115K – 2631
2023
Q2 		$115K Sell
8,924
-3,446
-28% -$46.6K ﹤0.01% 1959
2023
Q1 		$163K Buy
+12,370
New +$197K ﹤0.01% 1820
2022
Q4 		– Sell
-1,019
Closed -$12K – 2626
2022
Q3 		$12K Buy
+1,019
New +$13.8K ﹤0.01% 2850

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Verition Fund Management's RIGL Position: Q4 2025 in Review

Verition Fund Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2025, closing a stake of 13,489 shares — an estimated $382K sold.

Verition Fund Management first reported a position in RIGL in Q3 2022 and held it in 6 quarters. The position peaked at $382K in Q3 2025. 193 funds tracked by Wall St. Rank hold RIGL as of Q4 2025.

  • Verition Fund Management reported no remaining Rigel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 13,489 Rigel Pharmaceuticals shares in Q4 2025, an estimated $382K.
  • Verition Fund Management first reported a position in Rigel Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Verition Fund Management's Rigel Pharmaceuticals position peaked at $382K in Q3 2025.
  • 193 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.